ChemoTech’s distributor ABEX receives ‘Special Access’

Distributor Abex Medical System Sdn. Bhd. (ABEX), has together with “Pusat Perubatan Universiti Malaya” (PPUM), received 'Special Access', a special license to import IQWave™.

When ChemoTech signed the distributor agreement with ABEX in the beginning of the year, we were aware of the requirement of local registration prior to commercialization. A presentation of IQWave™ held at the oncology department at PPUM resulted in the hospital requesting "Special Access" at the authorities to import non-registered medical equipment or drugs in a country. The purpose of this license is that PPUM will be able to perform its desired clinical evaluation of IQWave™ D-EECT.

I feel extremely grateful that BEX has managed to obtain this license from the Ministry of Health (MOH) in Malaysia so quickly. This further strengthens our confidence in the distributor ABEX, says CEO Mohan Frick.

The evaluation study at PPUM is scheduled to start in September 2018.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Wednesday 16th of May 2018 at 09.30 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on NASDAQ First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.